Patch testing for nonimmediate cutaneous adverse drug reactions
To the Editor: Adverse drug reactions commonly involve the skin. Although medication rechallenge is the most reliable method for definitive diagnosis, there is inherent medical and legal risk with rechallenge. There is a paucity of other validated confirmatory tests. This research letter analyzes the published data on patch testing for nonimmediate cutaneous adverse drug reactions (NI-CADR). The methods used for the systematic literature search is presented in Fig 1. The results are organized on the basis of type of NI-CADR and presented in Table I . 1 Current guidelines recommend patch testing between 6 weeks and 6 months after resolution of NI-CADR and at least 1 month after discontinuation of oral steroids. Patch testing results for NI-CADR are reproducible in 89% of patients after a mean interval of 6.0 years. 2 European guidelines exist for testing of commercially available medications at 30% and 20% concentrations.
3 Exceptions to the guidelines exist. Location of patch testing is generally performed on the upper back, except for fixed drug eruptions, in which patch testing must be performed on previously affected skin. Results of patch tests are read according to the International Contact Dermatitis Research Group guidelines. 4 Most articles included in this review evaluated individual medications with high imputability; however, patch testing can be useful even when multiple drugs are suspected. J AM ACAD DERMATOL VOLUME 78, NUMBER 2 Clinically significant relapse with patch testing is rare. In a multicenter study analyzing safety of patch testing in 134 patients with severe NI-CADR, only 1 patient had a relapse requiring treatment with systemic steroids. 6 No other articles included in this review noted clinically significant relapse with patch testing. Physicians should be aware that patch testing appears to be safe and useful to confirm the culprit medication in many instances of NI-CADR. Likelihood of a positive patch test varies on the basis of the medication and type of cutaneous adverse reaction (Table I) . 1 If confirmation of the culprit medication is necessary and is not evident based on medical history alone, patch testing should be considered. Accuracy of death certification in cutaneous squamous cell carcinoma: A retrospective case review
To the Editor: Despite the high incidence of cutaneous squamous cell carcinoma (cSCC), its mortality rate remains uncertain. Mortality estimates have been derived primarily from death certificates because cSCC is not tracked by cancer registries in the United States. Previous studies of persons with death certificates implicating cSCC as cause of death found a 60% false-positive risk (ie, deaths due to other causes being misattributed to cSCC). [1] [2] [3] [4] However, because these cohorts were drawn from death certificate data, these studies could not assess the false-negative risk (ie, deaths due to cSCC being misattributed to other causes). The objective of this study was to determine the false-negative risk of cSCC mortality estimation by reviewing the death certificates of patients known to have died from cSCC. The Department of Pathology database was queried for patients diagnosed with cSCC at Brigham and Women's Hospital from January 1, 2000, through December 31, 2015, as was done previously through December 31, 2009. 5 Review of electronic medical records by Mr Karia identified patients with cSCC-specific mortality as designated by treating physicians in clinic notes, admission records, death notes, and other correspondences recorded in the electronic medical records. cSCC as the cause of death was assigned as definite, probable, possible, and not. Definite cases were those in which treating physicians clearly stated that the patient died from cSCC. Probable cases were those in which cSCC was the primary health issue causing the patient's decline and leading to death (eg, failure to thrive, pneumonia, sepsis, declining cardiac output, metabolic acidosis, and acute organ failure). Cases classified as definite or probable were considered as cSCC deaths in this study. Cases classified as possible (patients who had advanced cSCC but had other health issues that could have contributed equally or more so to their death) were not included. Ambiguous cases were reviewed and classified by Dr Schmults. Death certificates were obtained for these patients at the Massachusetts Registry of Vital Records and reviewed by Mr Wang for written causes of death and International Classification of Diseases, 10th Revision (ICD-10) codes, which have been used in the Massachusetts Registry of Vital Records since 1999. This study was approved by the Partners Human Research Committee.
Certificates were considered correctly classified if SCC was listed as the cause of death, ambiguously classified if a nonecSCC-specific designation (eg, skin cancer) was listed, and incorrectly classified if a noneskin cancer cause of death was listed.
A total of 28 patients during the study period died from cSCC and its direct complications. Excluding 5 deaths that occurred out of state, the study population consisted of 23 patients with cSCC-specific mortality for whom death certificates were obtainable. On written classification, 10 (43%) deaths were correctly classified, and 13 (57%) were ambiguously or incorrectly classified (Table I) . Three of the latter group were ambiguously classified as due to skin cancer or metastatic skin cancer without further specification, 8 were ambiguously classified by tumor location (eg, rectal cancer for a case of perianal cSCC), and 2 were incorrectly classified as due to noncancerous causes. ICD-10 codes were more inaccurate, with only 5 (22%) cases having a skin cancer code assigned (C44.9) and none specifically indicating cSCC. This is the first study to demonstrate a high falsenegative risk of cSCC mortality reporting on death certificates. In this cohort known to have died from cSCC, less than half (43%) had death certificates that specifically designated cSCC. cSCC generally carries a favorable prognosis, which accounts for the few deaths identified. However, this further emphasizes the potential for misclassified deaths to significantly skew estimated mortality rates. Given the results herein showing a 57% false-negative risk and prior studies showing a 60% false-positive risk, death certificate reporting of cSCC is highly inaccurate. Population-based studies not relying on death certificate reporting should be used to assess cSCC mortality until death certificate reporting can be substantially improved or cSCC is included within cancer registries.
